secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001628280-26-001764
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion reports preliminary 2025 revenue up 20-23%, U.S. sales up 35-38%; provides 2026 OpEx guidance
--------------------------------------------------------------------------------

- Preliminary 2025 U.S. net product sales $156-160M, up 35-38% YoY; total revenue $400-408M, up 20-23%.
- Cash and equivalents ~$168M at year-end 2025; completed $75M capital raise in 2025.
- 2026 operating expenses expected $210-245M, including $15M non-cash stock compensation.
- Patent settlements with four ANDA filers restrict generic entry until April 2040; no remaining patent challenges.
- R&D pipeline: nominated ESP-2001 (ACLY inhibitor) for primary sclerosing cholangitis; blockbuster potential >$1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026001764/0001628280-26-001764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026001764/espr-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer